nach oben

Erschienen in:

01.08.2015 | Preclinical study

Chronic oxidative stress causes estrogen-independent aggressive phenotype, and epigenetic inactivation of estrogen receptor alpha in MCF-7 breast cancer cells

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

The role of chronic oxidative stress in the development and aggressive growth of estrogen receptor (ER)-positive breast cancer is well known; however, the mechanistic understanding is not clear. Estrogen-independent growth is one of the features of aggressive subtype of breast cancer. Therefore, the objective of this study was to evaluate the effect of oxidative stress on estrogen sensitivity and expression of nuclear estrogen receptors in ER-positive breast cancer cells. MCF-7 cells chronically exposed to hydrogen peroxide were used as a cell model in this study, and their growth in response to 17-β estradiol was evaluated by cell viability, cell cycle, and cell migration analysis. Results were further confirmed at molecular level by analysis of gene expressions at transcript and protein levels. Histone H3 modifications, expression of epigenetic regulatory genes, and the effect of DNA demethylation were also analyzed. Loss of growth in response to estrogen with a decrease in ERα expression was observed in MCF-7 cells adapted to chronic oxidative stress. Increases in mtTFA and NRF1 in these cells further suggested the role of mitochondria-dependent redox-sensitive growth signaling as an alternative pathway to estrogen-dependent growth. Changes in expression of epigenetic regulatory genes, levels of histone H3 modifications as well as significant restorations of both ERα expression and estrogen response by 5-Aza-2′-deoxycytidine further confirmed the epigenetic basis for estrogen-independent growth in these cells. In conclusion, results of this study suggest that chronic oxidative stress can convert estrogen-dependent nonaggressive breast cancer cells into estrogen-independent aggressive form potentially by epigenetic mechanism.

Li Y, Meeran SM, Patel SN, Chen H, Hardy TM, Tollefsbol TO (2013) Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer. Mol Cancer 12:9. doi:10.1186/1476-4598-12-9 PubMedCentralCrossRefPubMed

Al Saleh S, Al Mulla F, Luqmani YA (2011) Estrogen receptor silencing induces epithelial to mesenchymal transition in human breast cancer cells. PLoS One 6(6):e20610. doi:10.1371/journal.pone.0020610 PubMedCentralCrossRefPubMed

Renoir JM, Marsaud V, Lazennec G (2013) Estrogen receptor signaling as a target for novel breast cancer therapeutics. Biochem Pharmacol 85(4):449–465. doi:10.1016/j.bcp.2012.10.018 CrossRefPubMed

Schacter JL, Henson ES, Gibson SB (2014) Estrogen regulation of anti-apoptotic Bcl-2 family member Mcl-1 expression in breast cancer cells. PLoS ONE 9(6):e100364. doi:10.1371/journal.pone.0100364 PubMedCentralCrossRefPubMed

Jordan VC, Brodie AM (2007) Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 72(1):7–25. doi:10.1016/j.steroids.2006.10.009 PubMedCentralCrossRefPubMed

Curtis Hewitt S, Couse JF, Korach KS (2000) Estrogen receptor transcription and transactivation: estrogen receptor knockout mice: what their phenotypes reveal about mechanisms of estrogen action. Breast Cancer Res 2(5):345–352PubMedCentralCrossRefPubMed

Viedma-Rodríguez R, Baiza-Gutman L, Salamanca-Gómez F, Diaz-Zaragoza M, Martínez-Hernández G, Ruiz Esparza-Garrido R, Velázquez-Flores MA, Arenas-Aranda D (2014) Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (review). Oncol Rep 32(1):3–15. doi:10.3892/or.2014.3190 PubMed

Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M (2005) Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 23(11):2469–2476. doi:10.1200/JCO.2005.01.172 CrossRefPubMed

Santen RJ, Fan P, Zhang Z, Bao Y, Song RX, Yue W (2009) Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells. Steroids 74(7):586–594. doi:10.1016/j.steroids.2008.11.020 CrossRefPubMed

10.

Gee JM, Robertson JF, Ellis IO, Nicholson RI (2001) Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 95(4):247–254CrossRefPubMed

11.

Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, Arteaga CL (2000) Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 60(20):5887–5894PubMed

12.

Le Romancer M, Poulard C, Cohen P, Sentis S, Renoir JM, Corbo L (2011) Cracking the estrogen receptor’s posttranslational code in breast tumors. Endocr Rev 32(5):597–622. doi:10.1210/er.2010-0016 CrossRefPubMed

13.

Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D, Cheng JQ (2008) MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 283(45):31079–31086. doi:10.1074/jbc.M806041200 PubMedCentralCrossRefPubMed

14.

Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, Jacob S, Majumder S (2008) MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 283(44):29897–29903. doi:10.1074/jbc.M804612200 PubMedCentralCrossRefPubMed

15.

Luqmani YA, Al Azmi A, Al Bader M, Abraham G, El Zawahri M (2009) Modification of gene expression induced by siRNA targeting of estrogen receptor alpha in MCF7 human breast cancer cells. Int J Oncol 34(1):231–242PubMed

16.

Yoshida T, Eguchi H, Nakachi K, Tanimoto K, Higashi Y, Suemasu K, Iino Y, Morishita Y, Hayashi S (2000) Distinct mechanisms of loss of estrogen receptor alpha gene expression in human breast cancer: methylation of the gene and alteration of trans-acting factors. Carcinogenesis 21(12):2193–2201CrossRefPubMed

17.

Dairkee SH, Nicolau M, Sayeed A, Champion S, Ji Y, Moore DH, Yong B, Meng Z, Jeffrey SS (2007) Oxidative stress pathways highlighted in tumor cell immortalization: association with breast cancer outcome. Oncogene 26(43):6269–6279. doi:10.1038/sj.onc.1210452 CrossRefPubMed

18.

Heirman I, Ginneberge D, Brigelius-Flohe R, Hendrickx N, Agostinis P, Brouckaert P, Rottiers P, Grooten J (2006) Blocking tumor cell eicosanoid synthesis by GP x 4 impedes tumor growth and malignancy. Free Radic Biol Med 40(2):285–294. doi:10.1016/j.freeradbiomed.2005.08.033 CrossRefPubMed

19.

Okada F, Shionoya H, Kobayashi M, Kobayashi T, Tazawa H, Onuma K, Iuchi Y, Matsubara N, Ijichi T, Dugas B, Hosokawa M (2006) Prevention of inflammation-mediated acquisition of metastatic properties of benign mouse fibrosarcoma cells by administration of an orally available superoxide dismutase. Br J Cancer 94(6):854–862. doi:10.1038/sj.bjc.6603016 PubMedCentralCrossRefPubMed

20.

Mahalingaiah PK, Singh KP (2014) Chronic oxidative stress increases growth and tumorigenic potential of MCF-7 breast cancer cells. PLoS One 9(1):e87371. doi:10.1371/journal.pone.0087371 PubMedCentralCrossRefPubMed

21.

Cavalieri E, Frenkel K, Liehr JG, Rogan E, Roy D (2000) Estrogens as endogenous genotoxic agents–DNA adducts and mutations. J Natl Cancer Inst Monogr 27:75–93CrossRefPubMed

22.

Wani G, Milo GE, D’Ambrosio SM (1998) Enhanced expression of the 8-oxo-7,8-dihydrodeoxyguanosine triphosphatase gene in human breast tumor cells. Cancer Lett 125(1–2):123–130CrossRefPubMed

23.

Yau C, Benz CC (2008) Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of estrogen receptor positive primary breast cancers. Breast Cancer Res 10(4):R61. doi:10.1186/bcr2120 PubMedCentralCrossRefPubMed

24.

Okoh VO, Garba NA, Penney RB, Das J, Deoraj A, Singh KP, Sarkar S, Felty Q, Yoo C, Jackson RM, Roy D (2015) Redox signalling to nuclear regulatory proteins by reactive oxygen species contributes to oestrogen-induced growth of breast cancer cells. Br J Cancer 112(10):1687–1702. doi:10.1038/bjc.2014.586 CrossRefPubMed

25.

Frasor J, El-Shennawy L, Stender JD, Kastrati I (2014) NFκB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms. Mol Cell Endocrinol. doi:10.1016/j.mce.2014.09.013 PubMed

26.

Hayashi SI, Kimura M (2015) Mechanisms of hormonal therapy resistance in breast cancer. Int J Clin Oncol 20(2):262–267. doi:10.1007/s10147-015-0788-5 CrossRefPubMed

27.

Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE (2001) Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 61(19):7025–7029PubMed

28.

Bovenzi V, Momparler RL (2001) Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells. Cancer Chemother Pharmacol 48(1):71–76CrossRefPubMed

29.

Jang ER, Lim SJ, Lee ES, Jeong G, Kim TY, Bang YJ, Lee JS (2004) The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene 23(9):1724–1736. doi:10.1038/sj.onc.1207315 CrossRefPubMed

30.

Ganie SAHE, Hamid A, Masood A, Zargar MA (2011) Long dose exposure of hydrogen peroxide (H₂O₂) in albino rats and effect of Podophyllum hexandrum on oxidative stress. Eur Rev Med Pharmacol Sci 15:906–915PubMed

31.

Hwang SLYG (2008) Neuroprotective effects of the citrus flavanones against H₂O₂-induced cytotoxicity in PC12 cells. J Agric Food Chem 56:859–864CrossRefPubMed

32.

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4):402–408. doi:10.1006/meth.2001.1262 CrossRefPubMed

33.

Okoh VO, Felty Q, Parkash J, Poppiti R, Roy D (2013) Reactive oxygen species via redox signaling to PI3K/AKT pathway contribute to the malignant growth of 4-hydroxy estradiol-transformed mammary epithelial cells. PLoS ONE 8(2):e54206. doi:10.1371/journal.pone.0054206 PubMedCentralCrossRefPubMed

34.

Conway K, Parrish E, Edmiston SN, Tolbert D, Tse CK, Geradts J, Livasy CA, Singh H, Newman B, Millikan RC (2005) The estrogen receptor-alpha A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study. Breast Cancer Res 7(6):R871–R880. doi:10.1186/bcr1315 PubMedCentralCrossRefPubMed

35.

Skliris GP, Nugent ZJ, Rowan BG, Penner CR, Watson PH, Murphy LC (2010) A phosphorylation code for oestrogen receptor-alpha predicts clinical outcome to endocrine therapy in breast cancer. Endocr Relat Cancer 17(3):589–597. doi:10.1677/ERC-10-0030 CrossRefPubMed

36.

Kondo N, Toyama T, Sugiura H, Fujii Y, Yamashita H (2008) miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer. Cancer Res 68(13):5004–5008. doi:10.1158/0008-5472.CAN-08-0180 CrossRefPubMed

37.

Di Leva G, Gasparini P, Piovan C, Ngankeu A, Garofalo M, Taccioli C, Iorio MV, Li M, Volinia S, Alder H, Nakamura T, Nuovo G, Liu Y, Nephew KP, Croce CM (2010) MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst 102(10):706–721. doi:10.1093/jnci/djq102 PubMedCentralCrossRefPubMed

38.

Xiong J, Yu D, Wei N, Fu H, Cai T, Huang Y, Wu C, Zheng X, Du Q, Lin D, Liang Z (2010) An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples. FEBS J 277(7):1684–1694. doi:10.1111/j.1742-4658.2010.07594.x CrossRefPubMed

39.

Bergqvist J, Elmberger G, Ohd J, Linderholm B, Bjohle J, Hellborg H, Nordgren H, Borg AL, Skoog L, Bergh J (2006) Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen. Eur J Cancer 42(8):1104–1112. doi:10.1016/j.ejca.2006.01.028 CrossRefPubMed

40.

Kurebayashi J, Otsuki T, Moriya T, Sonoo H (2001) Hypoxia reduces hormone responsiveness of human breast cancer cells. Jpn J Cancer Res 92(10):1093–1101CrossRefPubMed

41.

Stoner M, Saville B, Wormke M, Dean D, Burghardt R, Safe S (2002) Hypoxia induces proteasome-dependent degradation of estrogen receptor alpha in ZR-75 breast cancer cells. Mol Endocrinol 16(10):2231–2242. doi:10.1210/me.2001-0347 CrossRefPubMed

42.

Zhou Y, Yau C, Gray JW, Chew K, Dairkee SH, Moore DH, Eppenberger U, Eppenberger-Castori S, Benz CC (2007) Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 7:59. doi:10.1186/1471-2407-7-59 PubMedCentralCrossRefPubMed

43.

Dumont JA, Bitonti AJ, Wallace CD, Baumann RJ, Cashman EA, Cross-Doersen DE (1996) Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth Differ 7(3):351–359PubMed

44.

Gago-Dominguez M, Jiang X, Castelao JE (2007) Lipid peroxidation, oxidative stress genes and dietary factors in breast cancer protection: a hypothesis. Breast Cancer Res 9(1):201. doi:10.1186/bcr1628 PubMedCentralCrossRefPubMed

45.

Jezierska-Drutel A, Rosenzweig SA, Neumann CA (2013) Role of oxidative stress and the microenvironment in breast cancer development and progression. Adv Cancer Res 119:107–125. doi:10.1016/B978-0-12-407190-2.00003-4 PubMedCentralCrossRefPubMed

46.

Li Y, Yuan YY, Meeran SM, Tollefsbol TO (2010) Synergistic epigenetic reactivation of estrogen receptor-α (ERα) by combined green tea polyphenol and histone deacetylase inhibitor in ERα-negative breast cancer cells. Mol Cancer 9:274. doi:10.1186/1476-4598-9-274 PubMedCentralCrossRefPubMed

47.

Giacinti L, Claudio PP, Lopez M, Giordano A (2006) Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist 11(1):1–8. doi:10.1634/theoncologist.11-1-1 CrossRefPubMed

48.

Hervouet E, Cartron PF, Jouvenot M, Delage-Mourroux R (2013) Epigenetic regulation of estrogen signaling in breast cancer. Epigenetics 8(3):237–245. doi:10.4161/epi.23790 PubMedCentralCrossRefPubMed

49.

Felty Q, Singh KP, Roy D (2005) Estrogen-induced G1/S transition of G0-arrested estrogen-dependent breast cancer cells is regulated by mitochondrial oxidant signaling. Oncogene 24(31):4883–4893. doi:10.1038/sj.onc.1208667 CrossRefPubMed

50.

Felty Q, Xiong WC, Sun D, Sarkar S, Singh KP, Parkash J, Roy D (2005) Estrogen-induced mitochondrial reactive oxygen species as signal-transducing messengers. Biochemistry 44(18):6900–6909. doi:10.1021/bi047629p CrossRefPubMed

51.

Scarpulla RC (2006) Nuclear control of respiratory gene expression in mammalian cells. J Cell Biochem 97(4):673–683. doi:10.1002/jcb.20743 CrossRefPubMed

52.

Toki N, Kagami S, Kurita T, Kawagoe T, Matsuura Y, Hachisuga T, Matsuyama A, Hashimoto H, Izumi H, Kohno K (2010) Expression of mitochondrial transcription factor A in endometrial carcinomas: clinicopathologic correlations and prognostic significance. Virchows Arch 456(4):387–393. doi:10.1007/s00428-010-0895-7 PubMedCentralCrossRefPubMed

53.

Martinez-Outschoorn UE, Goldberg A, Lin Z, Ko YH, Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell A, Sotgia F, Lisanti MP (2011) Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biol Ther 12(10):924–938. doi:10.4161/cbt.12.10.17780 PubMedCentralCrossRefPubMed

54.

Liang X, Lu B, Scott GK, Chang CH, Baldwin MA, Benz CC (1998) Oxidant stress impaired DNA-binding of estrogen receptor from human breast cancer. Mol Cell Endocrinol 146(1–2):151–161CrossRefPubMed

55.

Lapidus RG, Nass SJ, Butash KA, Parl FF, Weitzman SA, Graff JG, Herman JG, Davidson NE (1998) Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res 58(12):2515–2519PubMed

56.

Li WG, Li QH, Tan Z (2005) Epigallocatechin gallate induces telomere fragmentation in HeLa and 293 but not in MRC-5 cells. Life Sci 76(15):1735–1746. doi:10.1016/j.lfs.2004.09.024 CrossRefPubMed

57.

Ramos EA, Camargo AA, Braun K, Slowik R, Cavalli IJ, Ribeiro EM, FeO Pedrosa, de Souza EM, Costa FF, Klassen G (2010) Simultaneous CXCL12 and ESR1 CpG island hypermethylation correlates with poor prognosis in sporadic breast cancer. BMC Cancer 10:23. doi:10.1186/1471-2407-10-23 PubMedCentralCrossRefPubMed

58.

Wei J, Han B, Mao XY, Wei MJ, Yao F, Jin F (2012) Promoter methylation status and expression of estrogen receptor alpha in familial breast cancer patients. Tumour Biol 33(2):413–420. doi:10.1007/s13277-011-0234-x CrossRefPubMed

59.

Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB, Davidson NE (1994) Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res 54(10):2552–2555PubMed

60.

Ferguson AT, Vertino PM, Spitzner JR, Baylin SB, Muller MT, Davidson NE (1997) Role of estrogen receptor gene demethylation and DNA methyltransferase.DNA adduct formation in 5-aza-2′deoxycytidine-induced cytotoxicity in human breast cancer cells. J Biol Chem 272(51):32260–32266CrossRefPubMed

61.

Girault I, Lerebours F, Amarir S, Tozlu S, Tubiana-Hulin M, Lidereau R, Bièche I (2003) Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res 9(4):1259–1266PubMed

62.

Keen JC, Garrett-Mayer E, Pettit C, Mack KM, Manning J, Herman JG, Davidson NE (2004) Epigenetic regulation of protein phosphatase 2A (PP2A), lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells. Cancer Biol Ther 3(12):1304–1312CrossRefPubMed

63.

Yan PS, Perry MR, Laux DE, Asare AL, Caldwell CW, Huang TH (2000) CpG island arrays: an application toward deciphering epigenetic signatures of breast cancer. Clin Cancer Res 6(4):1432–1438PubMed

64.

Pilat MJ, Schwab ED, Yao KL, Pienta KJ (1998) Examination of the DNA methylation properties in nontumorigenic and tumorigenic breast epithelial cell lines. Anticancer Res 18(4A):2575–2582PubMed

65.

Sogon T, Masamura S, Hayashi S, Santen RJ, Nakachi K, Eguchi H (2007) Demethylation of promoter C region of estrogen receptor alpha gene is correlated with its enhanced expression in estrogen-ablation resistant MCF-7 cells. J Steroid Biochem Mol Biol 105(1–5):106–114. doi:10.1016/j.jsbmb.2006.12.104 PubMedCentralCrossRefPubMed

66.

Nan X, Campoy FJ, Bird A (1997) MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 88(4):471–481CrossRefPubMed

67.

Billam M, Witt AE, Davidson NE (2009) The silent estrogen receptor–can we make it speak? Cancer Biol Ther 8(6):485–496. doi:10.4161/cbt.8.6.7582 PubMedCentralCrossRefPubMed

68.

Cunha S, Lin YC, Goossen EA, DeVette CI, Albertella MR, Thomson S, Mulvihill MJ, Welm AL (2014) The RON receptor tyrosine kinase promotes metastasis by triggering MBD4-dependent DNA methylation reprogramming. Cell Rep 6(1):141–154. doi:10.1016/j.celrep.2013.12.010 CrossRefPubMed

69.

Zhu WG, Otterson GA (2003) The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents 3(3):187–199CrossRefPubMed

70.

Dobosy JR, Selker EU (2001) Emerging connections between DNA methylation and histone acetylation. Cell Mol Life Sci 58(5–6):721–727CrossRefPubMed

71.

Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, Wang SM, Herman JG, Davidson NE (2000) Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res 60(24):6890–6894PubMed

72.

Kawai H, Li H, Avraham S, Jiang S, Avraham HK (2003) Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha. Int J Cancer 107(3):353–358. doi:10.1002/ijc.11403 CrossRefPubMed

73.

Varshochi R, Halim F, Sunters A, Alao JP, Madureira PA, Hart SM, Ali S, Vigushin DM, Coombes RC, Lam EWF (2005) ICI182,780 induces p21Waf1 gene transcription through releasing histone deacetylase 1 and estrogen receptor α from Sp1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line. J Biol Chem 280(5):3185–3196. doi:10.1074/jbc.M408063200 CrossRefPubMed

Titel: Chronic oxidative stress causes estrogen-independent aggressive phenotype, and epigenetic inactivation of estrogen receptor alpha in MCF-7 breast cancer cells
Publikationsdatum: 01.08.2015
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2015
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-015-3514-0

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Chronic oxidative stress causes estrogen-independent aggressive phenotype, and epigenetic inactivation of estrogen receptor alpha in MCF-7 breast cancer cells

Abstract

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

Deleterious BRCA1/2 mutations in an urban population of Black women

Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer

All eyes on the patient: the influence of oncologists’ nonverbal communication on breast cancer patients’ trust

Poly (I: C) modulates the immunosuppressive activity of myeloid-derived suppressor cells in a murine model of breast cancer

Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer

Localized experimental bone metastasis drives osteolysis and sensory hypersensitivity at distant non-tumor-bearing sites

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie